Brought to you by 
Genzyme licenses hernia repair product to CR Bard
Dec 2007
Executive Summary
Genzyme licensed CR Bard (vascular, urological, cancer, and surgical devices) manufacturing and marketing rights to its Sepramesh IP hernia repair line along with rights to use the Sepra bioresorbable coating technology in developing new products for hernia repair.
Deal Industry
- Biotechnology
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- Marketing-Licensing
- Product Purchase
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme licenses hernia repair product to CR Bard
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice